Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-15,400
Closed -$446K 127
2024
Q3
$446K Sell
15,400
-600
-4% -$17.5K 0.13% 118
2024
Q2
$448K Buy
16,000
+2,300
+17% +$63.3K 0.08% 156
2024
Q1
$380K Sell
13,700
-15,500
-53% -$430K 0.01% 234
2023
Q4
$841K Buy
29,200
+21,600
+284% +$653K 0.03% 210
2023
Q3
$252K Sell
7,600
-1,300
-15% -$46K 0.02% 338
2023
Q2
$326K Sell
8,900
-3,600
-29% -$140K 0.02% 285
2023
Q1
$510K Buy
12,500
+400
+3% +$17.3K 0.01% 257
2022
Q4
$620K Sell
12,100
-5,200
-30% -$249K 0.06% 240
2022
Q3
$76K Sell
17,300
-14,400
-45% -$700K 0.04% 215
2022
Q2
$59K Buy
31,700
+19,900
+169% +$1.01M 0.02% 249
2022
Q1
$27K Sell
11,800
-19,900
-63% -$1.03M ﹤0.01% 281
2021
Q4
$14K Buy
31,700
+13,500
+74% +$669K ﹤0.01% 393
2021
Q3
$49K Sell
18,200
-2,300
-11% -$102K 0.02% 291
2021
Q2
$21K Sell
20,500
-13,600
-40% -$529K 0.01% 365
2021
Q1
$40K Buy
34,100
+200
+0.6% +$7.1K ﹤0.01% 358
2020
Q4
$48K Buy
33,900
+11,450
+51% +$420K ﹤0.01% 304
2020
Q3
$31K Buy
22,450
+5,691
+34% +$200K ﹤0.01% 204
2020
Q2
$44K Buy
+16,759
New +$569K 0.01% 186
2019
Q1
Sell
-13,491
Closed -$1K 386
2018
Q4
$1K Sell
13,491
-211
-2% -$8.76K ﹤0.01% 342
2018
Q3
$1K Buy
+13,702
New +$527K ﹤0.01% 378

Other funds holding PFE

XR Securities's PFE Position: Q3 2024 in Review

XR Securities sold out of Pfizer (PFE) in Q3 2024, closing a stake of 7,794 shares — an estimated $227K sold.

XR Securities first reported a position in PFE in Q2 2020 and held it in 9 quarters. The position peaked at $1.36M in Q1 2021. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

  • XR Securities reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
  • XR Securities sold 7,794 Pfizer shares in Q3 2024, an estimated $227K.
  • XR Securities first reported a position in Pfizer in Q2 2020 and held it in 9 quarters.
  • XR Securities's Pfizer position peaked at $1.36M in Q1 2021.
  • 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on XR Securities's 13F filing for Q3 2024, filed 25 Oct 2024.